Results from a phase 3 open label trial (ClinicalTrials.gov Identifier: NCT01413178) published in The Lancet Haematology suggest that busulfan plus melphalan may result in longer progression-free survival (PFS) compared with melphalan alone in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation (HSCT). Patients with newly diagnosed multiple myeloma were accepted into the study…
The Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex (daratumumab; Janssen), which provides clinicians the option of splitting the first infusion of daratumumab over 2 consecutive days.
Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.
An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.
The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.
Although the effectiveness and safety of bortezomib-based therapy for patients with R/R MM has been demonstrated in phase 2 and phase 3 clinical trials, data collected from real-world settings appear to confirm prior study results.
In an analysis of 11 studies, researchers investigated whether the benefits of carfilzomib for multiple myeloma outweigh the cardiovascular risks. However, the researchers recommend careful monitoring and management of blood pressure and volume status as good clinical practice, regardless.
Repeat primary care consultations before a diagnosis was assigned and non-specific symptoms were two factors that caused delays in the diagnosis of patients with myeloma following the appearance of symptoms.